RBC Previews Bausch + Lomb's Q1

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

RBC Previews Bausch + Lomb's Q1

, MT Newswires - 11:45 AM ET 4/4/2025 Company News

11:45 AM EDT, 04/04/2025 (MT Newswires) -- Bausch + Lomb ( BLCO ) will report first-quarter results on April 30.

RBC is forecasting first-quarter revenue of US$1.15 billion, and adjusted EBITDA of US$161 million. Analyst Douglas Miehm expects the focus to be on the company's DED Rx drugs (Miebo/Xiidra), the impact and resolution timelines of the IOL recall and potential tariff related headwinds following Reciprocal Tariffs announced by the U.S.

The first quarter will continue to be influenced by FX headwinds (RBCe: US$24 million for Q1) which have moderated. Miehm estimates US$45 million for CY25 based on the current exchange rates compared with US$100 million previously.

Lowering target to US$17 from US$18 on revised estimates and updated multiples. Maintain Outperform.

Price: 17.25, Change: -1.03, Percent Change: -5.63

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.